Zentalis Pharmaceuticals (ZNTL)

• Market cap: $164M
• 1 day: -3.44%
• 5 days: -5.6%
• 1 month: 3.27%
• 3 months: 87.41%
• 6 months: 68.67%
• Year to date: 84.67%
• 1 year: 27.78%
• 5 years: -94.04%
• 10 years: -89.09%
• Sector: Healthcare
• Industry: Biotechnology

About: Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Employees: 166